首頁 > 市場調查報告書 > 製藥

骨疾病

市場調查報告書

商品編碼

2046588

骨生成激素市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、區域和競爭格局分類，2021-2031年

Bone Morphogenetic Protein Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F

出版日期: 2026年05月25日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球骨形成蛋白(BMP) 市場預計將從 2025 年的 7.4212 億美元成長到 2031 年的 9.0645 億美元，複合年成長率為 3.39%。

骨形態發生蛋白（BMP）是強效的生長因子，對刺激骨誘導至關重要，進而促進天然骨骼和軟骨的形成。該市場的主要驅動力是需要進行脊椎融合手術的退化性脊椎疾病盛行率的不斷上升，以及易受整形外科創傷影響的老年人口的成長。這些代表了潛在的臨床需求，與諸如先進的遞送載體等技術趨勢截然不同。然而，BMP療法的高成本顯著阻礙了市場擴張，使報銷流程複雜化，限制了對成本敏感的醫療保健計劃的可及性，再加上監管機構對潛在副作用的審查。美國脊椎註冊中心（American Spine Registry）的報告也印證了這項需求，報告顯示，2024年至2025年，參與機構的脊椎手術量較去年同期成長17.86%，凸顯了脊椎治療領域對先進生物解決方案的持續需求。

市場概覽
預測期	2027-2031
市場規模：2025年	7.4212億美元
市場規模：2031年	9.0645億美元
複合年成長率：2026-2031年	3.39%
成長最快的細分市場	脊椎融合手術
最大的市場	北美洲

市場促進因素

退化性脊椎疾病的日益普遍是骨形成蛋白(BMP) 市場的主要驅動力，因此需要先進的生物解決方案來提高融合率。隨著人口老化和久坐生活方式的增加，脊椎融合手術的數量也在增加，因此臨床上對能夠促進骨骼快速生長和穩定性的強效骨誘導劑的需求日益成長。主要行業參與者的強勁表現支撐了這一細分市場的擴張。Medtronic力顱腦與脊椎技術部門報告稱，2024 會計年度銷售額達 94 億美元，年增 5.0%，這主要得益於其核心脊椎業務的持續成長以及基礎技術的應用。這直接轉化為 BMP 用量的增加，以最大限度地降低複雜脊椎手術中不融合的風險。同時，運動相關損傷和創傷性骨折的激增也顯著推動了市場成長，因為這些情況通常需要生物材料加固，以促進嚴重病例和自體移植不足以修復的不融合病例的癒合。據美國國家安全委員會稱，預計到2024年，因運動和休閒受傷而前往急診室就診的人數將增加17%，這進一步凸顯了這一趨勢。國際骨質疏鬆症基金會報告稱，55歲及以上人群每年發生多達3700萬例脆性骨折，隨著全球人口老化，符合這些再生療法條件的患者群體正在擴大。

市場挑戰

骨形成蛋白（BMP）療法的高成本是限制市場發展的一大因素。高昂的價格往往導致保險公司製定嚴格的報銷方案和福利限制，阻礙了醫療機構將這些生物製藥作為標準治療方案。在對成本高度敏感的醫療環境下，醫院採購部門通常會限制昂貴骨誘導劑的使用，並優先選擇成本較低的合成替代品以維持預算平衡。這迫使管理者嚴格評估生物製藥的成本效益，將其應用範圍限制在最複雜的脊椎融合手術病例中，而非廣泛應用。手術報銷率的持續下降進一步加劇了這種經濟限制，擠壓了購買高品質骨移植替代物所需的營運利潤空間。例如，美國整形外科學會 (AAOS) 指出，2025 年 Medicare 醫師收費標準中的報銷率轉換係數年減了 2.83%，這將直接抑製手術中心的購買力，從而阻礙骨形成蛋白(BMP) 市場的成長。

市場趨勢

一個關鍵的市場趨勢是骨形成蛋白(BMP) 的臨床應用正擴展到口腔顎顏面外科領域，其用途不再局限於脊椎融合手術，還包括鼻竇增高術等牙科重組手術。這一趨勢的驅動力在於人工植牙領域對強效生物解決方案的需求，這些解決方案能夠修復骨缺損，從而確保植入手術的成功。作為佐證，士卓曼集團2025年第三季報告顯示，其銷售額實現了6.022億瑞士法郎的內部成長，增幅達8.3%，主要由植入推動，這證實了骨誘導因子在口腔外科手術方案中日益重要的地位，有助於提高穩定性和促進骨整合。同時，基於奈米技術的控釋遞送系統的應用，有效避免了傳統膠原蛋白載體常見的快速釋放問題，從而提高了治療安全性。創新研究人員正在開發奈米結構載體，以確保生長因子的持續局部釋放，促進局部骨形成，同時最大限度地減少全身不良反應。國際科學技術合作暨發展組織（IPC）於2025年12月報告了一項新型奈米工程移植材料的臨床試驗，證明了這項進展。該試驗顯示，粒狀骨再生率提高了75%，這對於最佳化這些再生蛋白的效用和安全性至關重要。

The Global Bone Morphogenetic Protein (BMP) Market is projected to grow from USD 742.12 Million in 2025 to USD 906.45 Million by 2031, achieving a 3.39% CAGR. BMPs are potent growth factors critical for stimulating osteoinduction, thereby facilitating natural bone and cartilage formation. The market is primarily supported by the increasing prevalence of degenerative spinal disorders requiring fusion surgeries and a growing geriatric population susceptible to orthopedic trauma; these are fundamental clinical necessities, distinct from technological trends like refined delivery carriers. However, market expansion is significantly impeded by the high costs of BMP therapies, which complicate reimbursement processes and limit accessibility in cost-sensitive healthcare systems, alongside regulatory scrutiny concerning potential adverse effects. Illustrating this demand, the American Spine Registry reported a 17.86% increase in submitted spinal procedure volumes in 2024 from participating institutions in 2025, underscoring a sustained need for advanced biologic solutions in spinal care.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 742.12 Million
Market Size 2031	USD 906.45 Million
CAGR 2026-2031	3.39%
Fastest Growing Segment	Spinal Fusion
Largest Market	North America

Market Driver

The increasing prevalence of degenerative spinal disorders serves as a primary catalyst for the Bone Morphogenetic Protein (BMP) market, necessitating advanced biologic solutions to ensure successful fusion rates. As the volume of spinal fusion procedures rises due to aging demographics and sedentary lifestyles, the clinical demand for potent osteoinductive agents intensifies to promote rapid bone growth and stability. This segment's expansion is evidenced by the robust financial performance of major industry players, with Medtronic's Cranial & Spinal Technologies division reporting $9.4 billion in revenue for Fiscal Year 2024, reflecting a 5.0% increase driven by sustained core spine growth and enabling technology adoption, directly amplifying BMP consumption to minimize non-union risks in complex spinal surgeries. Concurrently, a surge in sports-related injuries and traumatic fractures also significantly propels the market, as these often require biological augmentation to accelerate healing in severe or non-union cases where autograft is insufficient, further highlighted by a 17% increase in sports and recreational injury emergency department visits in 2024 per the National Safety Council. The global population's increasing fragility, with up to 37 million annual fragility fractures in individuals over 55 according to the International Osteoporosis Foundation, expands the addressable patient pool for these regenerative therapies.

Market Challenge

The high cost associated with Bone Morphogenetic Protein therapies constitutes a significant restriction on market progression, as elevated pricing structures frequently lead to rigorous reimbursement protocols and coverage limitations by insurance providers, thereby discouraging healthcare facilities from adopting these biologic solutions for standard procedures. In cost-sensitive healthcare environments, hospital procurement departments often restrict the use of expensive osteoinductive agents to maintain budget neutrality, preferring lower-cost synthetic alternatives, which forces administrators to strictly evaluate the cost-benefit ratio of biologics, limiting their usage to only the most complex spinal fusion cases rather than broad application. This economic constraint is further intensified by ongoing reductions in procedural reimbursement rates, which narrow the operating margins required to purchase premium bone graft substitutes; for instance, the American Academy of Orthopaedic Surgeons noted a 2.83 percent reduction in the Medicare Physician Fee Schedule's conversion factor for reimbursement rates in 2025 compared to the prior year, directly curbing surgical centers' purchasing power and thus hampering the volume growth of the Bone Morphogenetic Protein market.

Market Trends

A significant market trend involves the expansion of clinical applications for bone morphogenetic proteins (BMPs) into oral and maxillofacial surgery, diversifying usage beyond spinal fusion to include dental reconstructions like sinus lifts. This trend is accelerated by the dental implant sector's demand for potent biologic solutions to restore compromised bone sites for successful implantation, evidenced by the Straumann Group's Q3 2025 report of CHF 602.2 million in revenue and 8.3% organic growth, largely driven by implantology and confirming the rising integration of osteoinductive agents into oral surgical protocols for stability and osseointegration. Concurrently, the adoption of nanotechnology-based delivery systems for controlled release is improving therapeutic safety by preventing the burst release often seen in traditional collagen carriers; innovators are developing nanostructured vehicles that ensure the sustained, localized elution of growth factors, enhancing localized bone formation while minimizing adverse systemic effects. This progress is illustrated by clinical tests of a new nano-engineered graft, as reported by the Organization for Development of International Science and Technology Cooperation in December 2025, demonstrating up to a 75% boost in bone regeneration in granule form, which is crucial for optimizing the utility and safety profile of these regenerative proteins.

Key Market Players

Johnson & Johnson
Ember Therapeutics Inc
Integra LifeSciences Holdings Corp
Medtronic PLC
Bio-Techne Corp
Merck KGaA
Pfizer Inc
Stryker Corp
Thermo Fisher Scientific Inc
Zimmer Biomet Holdings Inc

Report Scope

In this report, the Global Bone Morphogenetic Protein Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bone Morphogenetic Protein Market, By Type

Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
Recombinant Human Bone Morphogenetic Protein (rhBMP) -7

Bone Morphogenetic Protein Market, By Application

Spinal Fusion
Trauma
Reconstructive Surgery
Oral-maxillofacial

Bone Morphogenetic Protein Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bone Morphogenetic Protein Market.

Available Customizations:

Global Bone Morphogenetic Protein Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bone Morphogenetic Protein Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7)
- 5.2.2. By Application (Spinal Fusion, Trauma, Reconstructive Surgery, Oral-maxillofacial)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Bone Morphogenetic Protein Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Bone Morphogenetic Protein Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Bone Morphogenetic Protein Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Bone Morphogenetic Protein Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Application

7. Europe Bone Morphogenetic Protein Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Bone Morphogenetic Protein Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Application
- 7.3.2. France Bone Morphogenetic Protein Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Bone Morphogenetic Protein Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Bone Morphogenetic Protein Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Bone Morphogenetic Protein Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Application

8. Asia Pacific Bone Morphogenetic Protein Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Bone Morphogenetic Protein Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Application
- 8.3.2. India Bone Morphogenetic Protein Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Bone Morphogenetic Protein Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Bone Morphogenetic Protein Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Bone Morphogenetic Protein Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Application

9. Middle East & Africa Bone Morphogenetic Protein Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Bone Morphogenetic Protein Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Application
- 9.3.2. UAE Bone Morphogenetic Protein Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Application
- 9.3.3. South Africa Bone Morphogenetic Protein Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Application

10. South America Bone Morphogenetic Protein Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Application
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Bone Morphogenetic Protein Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Application
- 10.3.2. Colombia Bone Morphogenetic Protein Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Application
- 10.3.3. Argentina Bone Morphogenetic Protein Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Bone Morphogenetic Protein Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Johnson & Johnson
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Ember Therapeutics Inc
15.3. Integra LifeSciences Holdings Corp
15.4. Medtronic PLC
15.5. Bio-Techne Corp
15.6. Merck KGaA
15.7. Pfizer Inc
15.8. Stryker Corp
15.9. Thermo Fisher Scientific Inc
15.10. Zimmer Biomet Holdings Inc